Breakthrough with CAR-NK Plus PD-1: Survival in Advanced Colorectal Cancer Exceeds 700 Days

In the treatment of advanced colorectal cancer (CRC), limited efficacy and high resistance rates have long posed major challenges. After failure of multiple lines of therapy, the median overall survival (OS) for patients is often less than one year, leaving very few effective treatment options.

Against this backdrop, a recent study on CAR-NK combined with PD-1 immunotherapy has delivered a notable breakthrough—some patients achieved an overall survival exceeding 700 days, reshaping current understanding of immunotherapy in advanced CRC.

This finding not only provides a new therapeutic direction for refractory solid tumors but also highlights the growing importance of combining cell-based immunotherapy with immune checkpoint inhibitors as a next-generation cancer treatment strategy.

---

Challenges in Advanced CRC: Limitations of Conventional Therapies

Colorectal cancer remains one of the most prevalent and deadly malignancies worldwide. For metastatic patients, although chemotherapy, anti-angiogenic therapies, and targeted drugs have evolved, overall outcomes remain suboptimal.

In real-world clinical practice, most patients eventually develop resistance after first- and second-line treatments, entering the “late-line treatment stage,” where:

• Conventional chemotherapy offers minimal benefit
• Targeted therapies apply only to specific patient subsets
• PD-1 monotherapy is mainly effective in MSI-H/dMMR populations

Studies show that only a small proportion of patients benefit from immune checkpoint inhibitors, making advanced CRC one of the most difficult solid tumors to treat with immunotherapy. Overcoming the “cold tumor” microenvironment has therefore become a critical scientific challenge.

---

CAR-NK Therapy: A Safer Next-Generation Alternative to CAR-T

Chimeric antigen receptor natural killer (CAR-NK) cells are emerging as a promising successor to CAR-T therapy.

Compared to CAR-T, CAR-NK offers several advantages:

• No strict HLA matching required, enabling “off-the-shelf” use
• Lower risk of cytokine release syndrome (CRS)
• Strong innate cytotoxic activity without prior antigen sensitization
• Better suitability for solid tumors

In this study, researchers used CAR-NK cells targeting NKG2D and incorporated IL-15 to enhance in vivo persistence and proliferation, thereby improving antitumor efficacy. This design allows CAR-NK cells to maintain both targeting precision and sustained activity.

---

Why Combine with PD-1? Unlocking Synergistic Effects

While CAR-NK therapy alone shows antitumor activity, immune suppression within the tumor microenvironment remains a major barrier.

Key findings include:

• T cells exhibit increased PD-1 expression after CAR-NK therapy (indicative of exhaustion)
• PD-L1 in the tumor microenvironment suppresses immune cell function

This suggests that CAR-NK alone may not achieve durable responses.

The addition of PD-1 inhibitors helps overcome these limitations by:

• Blocking the PD-1/PD-L1 pathway
• Restoring T cell and NK cell function
• Prolonging immune cell activity in vivo

Importantly, data showed that CAR gene expansion increased significantly—by approximately 45-fold—after PD-1 combination therapy, demonstrating strong synergy between the two approaches.

---

Clinical Highlights: Survival Beyond 700 Days

This Phase I study included six patients with advanced metastatic CRC who had failed multiple prior treatments.

Key results showed:

• Favorable overall safety profile
• No treatment-related deaths
• Adverse events were mainly mild and manageable (CRS and gastrointestinal symptoms)

Most notably:

• All patients in the combination group showed clinical benefit
• One patient achieved stable disease (SD)
• Two patients achieved overall survival exceeding 700 days (nearly two years)

This represents a significant advancement in late-stage CRC treatment.

For comparison:

• Traditional therapies: OS typically < 12 months
• Late-line patients: OS often < 6–8 months

The CAR-NK + PD-1 combination significantly extended survival in some patients, suggesting its potential to reshape treatment paradigms.

---

Safety Profile: More Controllable than CAR-T

Safety remains a central concern in cell therapy.

The study demonstrated:

• No severe neurotoxicity
• CRS events were mild and reversible
• No treatment-related mortality

Compared with the severe toxicities often associated with CAR-T therapy, CAR-NK shows a more favorable safety profile, supporting its potential for broader clinical application.

---

Industry Implications: A New Path for Solid Tumor Cell Therapy

While CAR-T has achieved success in hematologic malignancies, progress in solid tumors has been limited.

The emergence of CAR-NK combined with PD-1 offers a new solution:

• Enables off-the-shelf cell therapy approaches
• Reduces cost and treatment complexity
• Improves response rates in solid tumors

This strategy is rapidly becoming a global research focus and is widely regarded as a key direction for next-generation immunotherapy.

At the same time, as innovative therapies like CAR-NK enter clinical practice, demand for cross-border access, compliant drug supply, and patient support is increasing. Service platforms such as DengYueMed are playing an increasingly important role in helping patients access cutting-edge treatments more efficiently.

---

Future Outlook: Combination Therapy as the New Standard

Although current data are based on small cohorts, the signal is clear:

• Single-agent immunotherapy is insufficient for solid tumors
• Combination strategies represent the future

CAR-NK + PD-1 is only the beginning. Future approaches may further integrate:

• Antibody-drug conjugates (ADCs)
• Bispecific antibodies
• Radiopharmaceuticals

to form a multi-dimensional, synergistic treatment system.

---

Conclusion

The breakthrough of CAR-NK combined with PD-1 in advanced colorectal cancer marks a new stage in the evolution of cell therapy. Moving from single immune activation to multi-mechanism synergy, and from short-term response to long-term survival, this approach offers new hope for patients with refractory solid tumors.

As more clinical data emerge, this therapeutic strategy is expected to evolve from exploratory research into a standardized treatment option, ultimately delivering meaningful survival benefits to a broader patient population.